All results
30 results for randomized double blind placebo controlled study assess efficacy safety and
-
CTD-TCNPC-301
A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann…
- Ages
- 3 Years - N/A
- Sexes
- All
-
JNT-517
The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD)…
- Ages
- 18 Years - 65 Years
- Sexes
- All
-
Soleno C602
This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating…
- Ages
- 4 Years - N/A
- Sexes
- All
-
Armata
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…
- Ages
- 18 Years - N/A
- Sexes
- All
-
diSArm
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…
- Ages
- 18 Years - N/A
- Sexes
- All
-
CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK),…
- Ages
- 40 Years - N/A
- Sexes
- All
-
STOMP Gainesville
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or…
- Ages
- N/A - N/A
- Sexes
- All
-
PVT-2201-301
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
ATYR
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Adaptive COVID-19 Treatment Trial (ACTT)
This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized…
- Ages
- 18 Years - 99 Years
- Sexes
- All